BR112014000656A2 - formulações de vacina parenteral contra norovírus - Google Patents

formulações de vacina parenteral contra norovírus

Info

Publication number
BR112014000656A2
BR112014000656A2 BR112014000656A BR112014000656A BR112014000656A2 BR 112014000656 A2 BR112014000656 A2 BR 112014000656A2 BR 112014000656 A BR112014000656 A BR 112014000656A BR 112014000656 A BR112014000656 A BR 112014000656A BR 112014000656 A2 BR112014000656 A2 BR 112014000656A2
Authority
BR
Brazil
Prior art keywords
norovirus
vaccine formulations
parenteral vaccine
parenteral
formulations
Prior art date
Application number
BR112014000656A
Other languages
English (en)
Portuguese (pt)
Inventor
Richardson Charles
M Mendelman Paul
F Bargatze Robert
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47506489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014000656(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of BR112014000656A2 publication Critical patent/BR112014000656A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
BR112014000656A 2011-07-11 2012-07-11 formulações de vacina parenteral contra norovírus BR112014000656A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506447P 2011-07-11 2011-07-11
PCT/US2012/046222 WO2013009849A1 (en) 2011-07-11 2012-07-11 Parenteral norovirus vaccine formulations

Publications (1)

Publication Number Publication Date
BR112014000656A2 true BR112014000656A2 (pt) 2017-02-14

Family

ID=47506489

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000656A BR112014000656A2 (pt) 2011-07-11 2012-07-11 formulações de vacina parenteral contra norovírus

Country Status (29)

Country Link
US (5) US9801934B2 (https=)
EP (3) EP4112074A1 (https=)
JP (2) JP6208659B2 (https=)
KR (1) KR102096937B1 (https=)
CN (3) CN105031637A (https=)
AU (2) AU2012282658B2 (https=)
BR (1) BR112014000656A2 (https=)
CA (1) CA2841356C (https=)
CL (1) CL2014000082A1 (https=)
CR (2) CR20190540A (https=)
DK (1) DK3299030T3 (https=)
DO (2) DOP2014000004A (https=)
EA (3) EA035442B1 (https=)
EC (1) ECSP14013201A (https=)
ES (2) ES2656527T3 (https=)
GE (1) GEP201706668B (https=)
HK (2) HK1199202A1 (https=)
IL (1) IL230356B (https=)
MA (1) MA35414B1 (https=)
MX (2) MX379496B (https=)
MY (1) MY170746A (https=)
PE (1) PE20140845A1 (https=)
PH (3) PH12014500093A1 (https=)
PL (2) PL3299030T3 (https=)
SG (1) SG10201605644WA (https=)
TN (1) TN2014000008A1 (https=)
UA (1) UA117732C2 (https=)
WO (1) WO2013009849A1 (https=)
ZA (2) ZA201401012B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2066354B1 (en) 2006-09-29 2013-04-17 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
EP4112074A1 (en) 2011-07-11 2023-01-04 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
CN106103720A (zh) 2013-10-03 2016-11-09 武田疫苗股份有限公司 自细胞系检测和除去弹状病毒的方法
US20160310412A1 (en) 2013-12-16 2016-10-27 Takeda Pharmaceutical Company Limited Microneedle
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
GB201703644D0 (en) 2017-03-07 2017-04-19 Elopak As Improvements in or relating to toller mounting arrangements
EP3624851A1 (en) * 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US11633467B2 (en) 2018-02-15 2023-04-25 Icon Genetics Gmbh Immunogenic composition and vaccine for generating an immune response to norovirus
US20210121511A1 (en) * 2018-05-29 2021-04-29 Unm Rainforest Innovations Virus-like particle compositions and methods of using same
CN109265542B (zh) * 2018-09-27 2021-06-15 国药中生生物技术研究院有限公司 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用
AR117462A1 (es) * 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
WO2021140524A1 (en) 2020-01-08 2021-07-15 Bharat Biotech International Limited Viral vaccine compositions and methods of preparations thereof
WO2022210742A1 (ja) 2021-03-29 2022-10-06 デンカ株式会社 ノロウイルス由来のペプチド、ポリヌクレオチド、抗体、組成物、ノロウイルスの中和エピトープを同定する方法
US20240238401A1 (en) 2021-05-21 2024-07-18 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途
WO2025077799A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Method of preparing norovirus vaccine without adjuvant
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
EP0635056A1 (en) 1992-04-08 1995-01-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Wild-type measles virus glycoproteins: vaccine and detection method therefor
JPH08500250A (ja) 1992-09-07 1996-01-16 ベイラー・カレッジ・オブ・メディシン ノーウォークおよび関連ウイルスを検出し、かつ特徴付けるための方法並びに試薬
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
ATE328068T1 (de) 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
PT973546E (pt) 1997-04-08 2004-06-30 Merck & Co Inc Formulacoes estabilizadas de virus de papiloma humano
AU750702B2 (en) 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
HUP0103091A3 (en) 1998-08-14 2002-03-28 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
WO2000035479A1 (en) 1998-12-17 2000-06-22 Merck & Co., Inc. Synthetic virus-like particles with heterologous epitopes
AU764138B2 (en) * 1999-02-05 2003-08-14 Merck Sharp & Dohme Corp. Human papilloma virus vaccine formulations
KR100771402B1 (ko) 1999-06-22 2007-10-30 국립감염증연구소장이 대표하는 일본국 Ｓｒｓｖ 검출 킷트
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US20040121465A1 (en) 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
JP2006507800A (ja) 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
BR0311995A (pt) 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
CA2514667C (en) 2003-01-30 2013-01-08 Chiron Corporation Adjuvanted influenza vaccine
US20040213745A1 (en) 2003-02-20 2004-10-28 Vincent Sullivan Powder formulations of rSEB for improved vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2005032457A2 (en) 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants
JP2007537137A (ja) 2003-09-24 2007-12-20 モンタナ ステート ユニバーシティ ノロウィルスモノクローナル抗体及びペプチド
WO2005037223A2 (en) 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US20060177468A1 (en) 2005-01-05 2006-08-10 Philadelphia Health and Education Corporation (d/b/a Drexel University College of Medicine Delivery vehicles, bioactive substances and viral vaccines
EP1846439A2 (en) 2005-01-31 2007-10-24 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
ZA200707413B (en) 2005-03-18 2009-01-28 Cytos Biotechnology Ag Cat allergen fusion proteins and uses thereof
BRPI0611336A2 (pt) 2005-06-01 2010-08-31 Dow Global Technologies Inc método para produzir uma partìcula multivalente semelhante a vìrus, partìcula multivalente semelhante a vìrus, método de aumentar a solubilidade de uma partìcula multivalente semelhante a vìrus e vacina
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
US20080029915A1 (en) * 2006-08-02 2008-02-07 Courtoy Nv Rotary tablet press
EP2066354B1 (en) 2006-09-29 2013-04-17 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
PT2121011E (pt) 2006-12-06 2014-07-31 Novartis Ag Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
WO2008113011A2 (en) * 2007-03-14 2008-09-18 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
AU2008299589B2 (en) 2007-09-12 2014-06-26 Australian Centre For Plant Functional Genomics Pty Ltd Plant seed active transcriptional control sequences
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
NO2324113T3 (https=) 2008-08-08 2018-07-28
WO2010084298A1 (en) * 2009-01-22 2010-07-29 Pharmathene Uk Limited Stable vaccine compositions and methods of use
EA201171032A1 (ru) * 2009-02-10 2012-02-28 Новартис Аг Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
CA2787666A1 (en) 2010-01-21 2011-07-28 Ligocyte Pharmaceuticals, Inc. Targeted heterologous antigen presentation on calicivirus virus-like particles
CA2798739A1 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
EP4112074A1 (en) 2011-07-11 2023-01-04 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
EP3827838B1 (en) 2015-12-16 2023-06-07 The Walter and Eliza Hall Institute of Medical Research Inhibition of cytokine-induced sh2 protein in nk cells
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
KR20210005240A (ko) 2018-05-03 2021-01-13 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 면역 관문 차단과 함께 키메라 항원 수용체를 발현하도록 가공된 천연 킬러 세포
US20210308249A1 (en) 2018-08-20 2021-10-07 Takeda Vaccines, Inc. Vlp formulations
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
PE20211959A1 (es) 2019-02-15 2021-09-30 Editas Medicine Inc Celulas asesinas naturales (nk) modificadas para inmunoterapia

Also Published As

Publication number Publication date
CN103874507A (zh) 2014-06-18
UA117732C2 (uk) 2018-09-25
WO2013009849A1 (en) 2013-01-17
PH12014500093A1 (en) 2014-03-17
HK1215154A1 (zh) 2016-08-19
DOP2022000030A (es) 2022-06-30
EP2731621B1 (en) 2017-11-01
ES2656527T3 (es) 2018-02-27
MX2014000411A (es) 2014-08-26
AU2012282658B2 (en) 2014-11-27
EP2731621A4 (en) 2015-03-25
PE20140845A1 (es) 2014-08-03
JP6208659B2 (ja) 2017-10-04
MY170746A (en) 2019-08-27
SG10201605644WA (en) 2016-09-29
US20210085778A1 (en) 2021-03-25
ZA201401012B (en) 2015-05-27
NZ620865A (en) 2015-08-28
EA201792407A2 (ru) 2018-03-30
US11701420B2 (en) 2023-07-18
US20130273102A1 (en) 2013-10-17
US9801934B2 (en) 2017-10-31
EA029470B1 (ru) 2018-03-30
CA2841356A1 (en) 2013-01-17
US20160000899A1 (en) 2016-01-07
US10675341B2 (en) 2020-06-09
MX379496B (es) 2025-03-11
HK1199202A1 (en) 2015-06-26
ES2926487T3 (es) 2022-10-26
JP2014520852A (ja) 2014-08-25
PL2731621T3 (pl) 2018-10-31
CR20140069A (es) 2014-06-27
US9867876B2 (en) 2018-01-16
PH12018501515A1 (en) 2019-02-04
PH12021551773A1 (en) 2022-08-01
EA201490258A1 (ru) 2014-05-30
ECSP14013201A (es) 2014-05-31
EA035442B1 (ru) 2020-06-17
JP2017214357A (ja) 2017-12-07
IL230356B (en) 2019-05-30
PL3299030T3 (pl) 2022-12-05
GEP201706668B (en) 2017-05-25
EA202090699A3 (ru) 2020-11-30
EA201792407A3 (ru) 2018-07-31
EP4112074A1 (en) 2023-01-04
US20230338503A1 (en) 2023-10-26
US20180185468A1 (en) 2018-07-05
MX356586B (es) 2018-06-05
EA202090699A2 (ru) 2020-07-31
DK3299030T3 (da) 2022-09-05
EP3299030A1 (en) 2018-03-28
JP6613259B2 (ja) 2019-11-27
TN2014000008A1 (en) 2015-07-01
CA2841356C (en) 2022-03-01
MA35414B1 (fr) 2014-09-01
AU2015200836B2 (en) 2016-08-25
KR102096937B1 (ko) 2020-04-03
CN108567975A (zh) 2018-09-25
AU2012282658A1 (en) 2013-03-14
DOP2014000004A (es) 2014-10-31
NZ710919A (en) 2017-12-22
CN105031637A (zh) 2015-11-11
CL2014000082A1 (es) 2014-07-04
CR20190540A (es) 2022-04-04
EP3299030B1 (en) 2022-06-08
EP2731621A1 (en) 2014-05-21
AU2015200836A1 (en) 2015-03-12
ZA201500915B (en) 2016-06-29
KR20140066160A (ko) 2014-05-30
PH12018501515B1 (en) 2022-02-18
HK1198136A1 (en) 2015-03-13

Similar Documents

Publication Publication Date Title
BR112014000656A2 (pt) formulações de vacina parenteral contra norovírus
EP2684880A4 (en) DISPIROPYRROLIDINDERIVAT
EP2763776A4 (en) IMPROVED DISTRIBUTION ARRANGEMENT
PT2906251T (pt) Conjugados de pirrolobenzodiazepina-anticorpo anti-cd22
SMT201900181T1 (it) Metodi di preparazione di coniugati
EP2791103A4 (en) BETULINDERIVATE
BR112013018951A2 (pt) formulações de testosterona
FIU20110029U0 (fi) Säädettävä tolppakiinnitin
BR112014004779A2 (pt) formulações de derivados de decitabina
HUE044772T2 (hu) Immunogén készítmény
EP2791653A4 (en) PROCESS FOR OPTIMIZED SCATTEROMETRY
BR112014005756A2 (pt) vacina
EP2800129A4 (en) CONNECTION STRUCTURE
DK3498313T3 (da) Rørformede proteser
CO6960557A2 (es) Derivados de 2-yodo-imidazol
CO6920301A2 (es) Derivados insecticidas de 2-metoxibenzamida
CO6960544A2 (es) Preparación de liberación sostenida
IL231660A0 (en) Composition
FR2975564B1 (fr) Charrue
PL2762466T3 (pl) Pochodna fenylu
EP2751084A4 (en) YRIMIDINCARBOXAMIDDERIVATE
DK2672817T3 (da) Forbedrede insekticide formuleringer
EP2763699A4 (en) VACCINE
HRP20181667T1 (hr) Pripravak
DK2748612T3 (da) Forbedret vaccinediagnostik

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B25G Requested change of headquarter approved

Owner name: TAKEDA VACCINES INC (US)

B12B Appeal against refusal [chapter 12.2 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time